In August 2025, the WHO updated its Model List of Essential Medicines to include new vaccines targeting emerging infectious diseases, reflecting the evolving global health landscape. This inclusion underscores the importance of these vaccines in addressing public health challenges and encourages their widespread adoption.
In November 2025, the EMA introduced revised guidelines for the Vaccine Antigen Master File (VAMF) certification system, aiming to streamline the approval process for vaccines containing multiple antigens. These revisions are expected to reduce administrative burdens and expedite the availability of complex vaccines in the EU market.
In January 2026, the CDSCO implemented new regulations requiring enhanced pharmacovigilance reporting for vaccine manufacturers, emphasizing the importance of monitoring adverse events post-licensure. This initiative aims to strengthen the safety profile of vaccines and maintain public trust in immunization programs.
In March 2026, the FDA announced the approval of a novel vaccine developed using mRNA technology, marking a significant advancement in vaccine development. This approval highlights the potential of innovative platforms to address unmet medical needs and sets a precedent for future vaccine approvals.
In May 2026, the NPPA conducted a review of vaccine pricing in India, ensuring that essential vaccines remain affordable and accessible to the population. This review reflects the government's commitment to public health and the importance of vaccines in disease prevention.
These developments indicate a dynamic regulatory environment, with ongoing efforts to enhance vaccine accessibility, safety, and innovation globally.
